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U.S. National Commission for the Protection of Human Subjects of Biomedical
and Behavioral Research, called for a moratorium on prisoner experimentation. 6
These institutions further advocated the development of standards to regulate
medical experimentation in the prison setting and to safeguard the welfare of
prisoners who were included in clinical trials. 7
Subsequently, regulations regarding the use of biomedical experimentation
on prisoners were issued by the federal government. Department of Health and
Human Services ("DHHS") regulations 8 limit inmate participation in clinical
investigations to the following: (I) studies of the possible causes, effects, and
processes of imprisonment and criminal behavior so long as the research involves
only minimal risk and inconvenience to the subject; (2) studies of prisons as
institutional entities or of inmates as incarcerated individuals, so long as the
research involves only minimal risk and inconvenience to the subject; (3)
research on particular conditions affecting prisoners as a class so long as the
research is approved by the Secretary of Health and Human Services or an
authorized DHHS employee ("Secretary"); and (4) research involving a treatment
likely to benefit the prisoner himself or herself. 9 In addition, the institutional
review boardassessing the clinical trial must include at least one prisoner or
prisoner representative 10 and must certify that a variety of conditions have been
met and that a number of precautions have been taken." As a result of these and
other stringent requirements, only about fifteen percent of institutions engaging
in clinical research in the United States include prisoners in their research
protocols. 12
Abuse of prisoner subjects in biomedical research or failure to obtain
meaningful informed consent from inmates can lead to violations of their
constitutional rights. The constitutional provisions that may be implicated in
controversies regarding biomedical experimentation on prisoners include the
Fourth Amendment, Eighth Amendment, and Fourteenth Amendment.
Nevertheless, prohibiting seriously ill prisoners from participating voluntarily in
clinical research may constitute an equivalent contravention of their
constitutional rights under the Eighth Amendment and the Due Process and Equal

6. See ENCYCLOPEDIA OF BIOETHICS, supra note 1, at 2056.
7. See id.; REPORT, supra note 2.
8. Additional Protections Pertaining to Biomedical and Behavioral Research Involving
Prisoners as Subjects, 45 C.F.R. § 46.301 (1998).
9. See 45 C.F.R. § 46.306(a)(2). If a prisoner might be assigned to a placebo control arm,
the study can proceed only with approval by the Secretary. See id. § 46.306(a)(2)(iv).
10. See id. § 46.304(b).
11. See id. § 46.305(c).
12. Interview with Paula Knudson, Executive Coordinator ofthe University ofTexas Health
Science Center Committee for the Protection of Human Subjects (Sept. 18, 1998). See also Reid
J. Schar, Downward Sentencing Departures for HIV-Infected Defendants: An Analysis ofCurrent
Law and a Framework for the Future, 91 Nw. U. L. REv. 1147, 1185 n.235 (1997) ("Only 18% of
state and federal prisons offer experimental drugs and only 12% allow inmates access to clinical
trials of drugs.").
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Protection clauses. Because many clinical trials involve potential cures for
diseases that frequently affect prison populations, such as hepatitis, 13 HIV
infection, and tuberculosis, 14 regulations that are excessively stringent may
deprive prisoners of life-saving therapy. 15 Currently, 1.8 million people are in
jail in the United States at any given time. 16 Therefore, polices that bar prisoner
participation in biomedical research adversely affect a very large number of
Americans.
This Article will analyze the constitutional issues implicated in biomedical
research involving prisoners. It will argue that, in light of contemporary
regulatory safeguards, the constitutional rights of prisoners enrolled in clinical
studies will not be jeopardized. Moreover, the Article will encourage the
inclusion of prisoner subjects in biomedical research involving potentially
beneficial experimental treatment for life-threatening diseases and will assert that
regulations banning the inclusion of prisoners in clinical studies are
constitutionally suspect. This Article begins with an overview of clinical trials
and informed consent. Next, a brief history ofthe abuses suffered by prisoners
in clinical trials will be presented. The Article will then discuss the Nuremberg
Code and the federal regulations applicable to research involving inmates. The
constitutional issues relating to prisoners' participation in or exclusion from
clinical trials will be analyzed at length. Finally, the author will address the
practical and ethical difficulties of conducting biomedical experimentation in
which prisoners participate and will provide specific recommendations regarding
these impediments.
I. CLINICAL TRIALS AND INFORMED CONSENT

Clinical trials for drugs and devices are regulated by the Food and Drug
Administration (FDA). 17 Clinical trials for procedures such as surgeries or bone
marrow transplants are not regulated by the FDA but often must comply with
DHHS regulations. 18 Drugs studied in clinical trials are called Investigational
New Drugs ("INDs"). 19 Sponsors wishing to conduct a clinical trial to test a new

13. See 45 C.F.R. § 46.306(a)(2)(iii).
14. See Schar, supra note 12, at 1156.
15. See id. at 1184-85.
16. See Walter Shapiro, 1.8M Reasons for Criminal-Justice Reform, USA TODAY, Mar. 17,
1999, at 2A.
17. See 21 C.F.R. § 7.3(f) (1999) ("Product means an article subject to the jurisdiction of
the Food and Drug Administration, including any food, drug, and device intended for human or
animal use .... ").
18. See 45 C.F.R. § 46.101 (applicable to any research that is conducted, funded, or
regulated by any federal department or agency); Richard S. Saver, Note, Reimbursing New
Technologies: Why Are the Courts Judging Experimental Medicine?, 44 STAN. L. REv. 1095,
1110-11, 1122 (1992).
19. See 21 C.F.R. § 312.23(a).
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drug must submit an IND application to the FDA. 20 In some circumstances, a
drug still under investigation may be used to treat patients not participating in a
clinical trial. 21 Specifically, an IND may be used in treatment of patients if the
drug is intended to treat a serious or immediately life-threatening disease, 22 and
there is no comparable or satisfactory alternative drug ortherapy. 23 The drug can
be utilized in treatment if it is currently under investigation in a clinical trial, or
if clinical trials have been completed and the sponsor is actively pursuing
marketing approval with due diligence. 24
Medical research for drugs and other treatments is conducted in three or four
phases of clinical trials. 25 In Phase I, the new drug is given to patients or healthy
individuals to determine its toxicity, most effective method ofadministration, and
safe dosage range. 26 Participants in the trial receive increasing dosages of the
substance in order to determine its metabolism, absorption, and side effects and
to gain early evidence of its effectiveness, if possible. 27 Phase I clinical trials
generally involve only twenty to eighty subjects, last about a year, and have a
very high failure rate. 28 Seventy percent of drugs submitted for Phase I clinical
trials fail to progress to Phase II. 29
Phase II trials are designed to determine the effectiveness of the therapy. 30
The treatment is administered to patients afflicted with the disease for which the
therapy is intended, and the trial often involves 100 to 300 people and lasts about
two years. 31 Approximately thirty-three percent of drugs submitted for clinical
trials fail in Phase II testing. 32
Phase III clinical trials are conducted only after the treatment has proven
effective through Phase I and II trials. 33 The third phase attempts to assess the
medical results of the experimental therapy in comparison with standard therapy
or no therapy at all. 34 Phase III studies usually involve 1000 to 3000 patients and
last about three years. 35

See id.
See id. § 312.34(a).
See id. § 312.34(b)(I).
See id. § 31.234(b)(ii).
See id. § 312.34(b)(iv).
See id. § 312.21(a)-(c); see also Veronica Henry, Problems with Pharmaceutical
Regulation in the United States, 14 J. LEGAL MED. 617, 621 ( 1993 ).
26. See 21 C.F.R. § 312.21(a) (1999); see also Henry, supra note 25, at 621.
27. See 21 C.F.R. § 312.21(a); Henry, supra note 25, at 621.
28. See 21 C.F.R. § 312.21(a); Henry, supra note 25, at 621.
29. See Henry, supra note 25, at 621.
30. See 21 C.F.R. § 312.21(b).
31. See Henry, supra note 25, at 621.
32. See id.
33. See id.; see also 21 C.F.R. § 312.21.
34. See Henry, supra note 25, at 621; 21 C.F.R. § 312.21 (1999).
35. See Henry, supra note 25, at 621.
20.
21.
22.
23.
24.
25.
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The FDA may also require postmarketing or Phase IV clinical trials. 36 These
studies are designed to determine the existence of less common adverse
reactions, the effect of the drug on morbidity or mortality, and the effect of the
drug on a particular patient population, such as children. 37
Research that is conducted, supported, or regulated by any federal
department or agency must be reviewed by an Institutional Review Board
("IRB"). 38 An IRB is a committee designated by an institution to review,
approve, and periodically monitor biomedical research studies. 39 The IRB
receives a document known as the "protocol" regarding each clinical trial, which
describes eligibility requirements for participants, the number of subjects to be
tested, and the objective of the research. 40 Each participant must sign an
"informed consent" document through which he or she is fully informed of the
details of the clinical trial. 41
Both IRBs and the contents of informed consent forms are extensively
regulated by the Department of Health and Human Services. Each IRB must
have at least five members with varying backgrounds and diversity in terms of
race, gender, and culture. 42 Each IRB must include at least one member whose
principal concerns are in the scientific realm and one individual whose primary
concerns are nonscientific (e.g. a lawyer or minister). 43 Furthermore, each IRB
must include at least one member who is not otherwise affiliated with the entity
and who has no immediate family member affiliated with the institution. 44
Unless an expedited review is necessary, research protocols must be
reviewed at meetings at which a majority of the members of the IRB are present,
including at least one member whose professional expertise is nonscientific. 45
A majority of the members present must vote for the approval of the research
before the medical investigator is permitted to proceed. 46
An IRB has authority to approve or disapprove the research activities it
reviews or to require that they be modified. 47 The IRB must provide written
notification of its decisions to those who proposed the research and must conduct
continuing reviews of research it approved at least yearly, or more often if the
risks entailed necessitate a more frequent assessment. 48
In order to approve proposed research, an IRB must ensure that specific

36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.

See 21 C.F.R. § 312.85.
See id.; see also Henry, supra note 25, at 622.
See 45 C.F.R. §§ 46.101(a); 46.103 (1998).
See 21 C.F.R. § 56.102(g); 45 C.F.R. § 46.102(g) (1998).
See 21 C.F.R. § 56.115; 45 C.F.R. § 46.115.
See 21 C.F.R. § 50.20; 45 C.F.R. § 46.116.
See 21 C.F.R. § 56.107(a); 45 C.F.R. § 46.l07(a).
See 21 C.F.R. § 56.107(c); 45 C.F.R. § 46.107(c).
See 21 C.F.R. § 56.107(d); 45 C.F.R. §§ 46.107(d).
See 21 C.F.R. § 56.108(c); 45 C.F.R. § 46.108(b).
See 21 C.F.R. § 56.1 08( c); 45 C.F.R. § 46.1 08(b ).
See 21 C.F.R. § 56.109(a); 45 C.F.R. § 46.109(a).
See 21 C.F.R. § 56.1 09(e), (f); 45 C.F.R. § 46.109(d), (e).
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criteria are met. These include: ( 1) risks to participants are minimized; (2) risks
to subjects are reasonable in light of anticipated benefits; and (3) selection of
participants is equitable, and the protocol is sensitive to the particularized
problems of research involving vulnerable populations, such as children,
prisoners, pregnant women, mentally disabled individuals, or economically or
educationally deprived persons. 49
The information provided to participants on the informed consent document
must be written in language that is comprehensible to the subject. 50 Informed
consent may not include language that waives or appears to waive any of the
subject's rights or releases the institution or personnel involved in the research
from liability for negligence. 51 The regulations further require that informed
consent be obtained in writing from each participant, though certain exceptions
are allowed. 52
The regulations detail the data that must be featured on the informed consent
documentation. This information includes a description of the research, an
explanation of its risks, benefits, and alternatives, a discussion of confidentiality,
a list of contact people, and a statement that participation is voluntary and may
be discontinued at any time. 5 3

49. See 21 C.F.R. § 56.111 (a); 45 C.F.R. § 46.111 (a).
50. See 21 C.F.R. § 50.20; 45 C.F.R. § 46.116.
51. See 21 C.F.R. § 50.20; 45 C.F.R. § 46.116.
52. See 21 C.F.R. § 50.27; 45 C.F.R. § 46.117.
53. See 21 C.F.R. § 50.25(a), (b); 45 C.F.R. § 46.116(a), (b). The provision reads in part
as follows:
{a) Basic elements of informed consent. ... in seeking informed consent the following
information shall be provided to each subject:
(1)

A statement that the study involves research, an explanation of the purposes
of the research and the expected duration of the subject's participation, a
description of the procedures to be followed, and identification of any
procedures which are experimental;

{2)

A description of any reasonably foreseeable risks or discomforts to the
subject;

(3)

A description of any benefits to the subject or to others which may
reasonably be expected from the research;

(4)

A disclosure of appropriate alternative procedures or courses of treatment,
if any, that might be advantageous to the subject;

(5)

A statement describing the extent, if any, to which confidentiality of records
identifying the subject will be maintained;

(6)

For research involving more than minimal risk, an explanation as to whether

2000]

PRISONER PARTICIPATION IN CLINICAL TRIALS

481

While extensive federal regulations protect contemporary research subjects
in the United States, regulatory safeguards are a relatively recent phenomenon. 54
Absent governmentally-mandated constraints, medical researchers often abused
and even tortured those involved in clinical trials, particularly when the
participants were prisoners. The history of medical experimentation on prisoners
both in this country and abroad is grim and sobering.

any compensation and an explanation as to whether any medical treatments
are available if injury occurs and, if so, what they consist of, or where further
information may be obtained;
(7)

An explanation of whom to contact for answers to pertinent questions about
the research and research subjects' rights, and whom to contact in the event
of a research-related injury to the subject; and

(8)

A statement that participation is voluntary, refusal to participate will involve
no penalty or loss of benefits to which the subject is otherwise entitled, and
the subject may discontinue participation at any time without penalty or loss
of benefits to which the subject is otherwise entitled.

(b)

Additional elements of informed consent. When appropriate, one or more of
the following elements of information shall also be provided to each subject:
(I)

A statement that the particular treatment or procedure may involve risks to
the subject (or to the embryo or fetus, if the subject is or may become
pregnant) which are currently unforseeable;

(2)

Anticipated circumstances under which the subject's participation may be
terminated by the investigator without regard to the subject's consent;

(3)

Any additional costs to the subject that may result from participation in the
research;

(4)

The consequences of a subject's decision to withdraw from the research and
procedures for orderly termination of participation by the subject;

(5)

A statement that significant new findings developed during the course of the
research which may relate to the subject's willingness to continue
participation will be provided to the subject; and

(6) The approximate number of subjects involved in the study.
45 C.F.R. § 46.116(a)-(b) (1998).
54. The relevant federal regulations were promulgated only in the 1970s, as discussed in Part
III below.
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THE ABUSE OF PRISONERS IN CLINICAL TRIALS

Throughout history many different cultures used prisoners for biomedical
experimentation. In ancient Persia physicians were permitted to utilize
incarcerated individuals as research subjects. 55 The Roman empire subjected
prisoners to the testing of poisons. 56 Eighteenth century European physicians
exposed prisoners to venereal disease, cancers, typhoid, and scarlet fever in order
to conduct medical research. 57
In the United States the earliest known experimentation involving prisoners
dates back to 1914, when white male convicts in Mississippi were used in
pellagra studies. 58 Pellagra is a disease that causes dermatitis, diarrhea, dementia,
and, at times, death. 59 The purpose of the experiment was to induce pellagra in
twelve volunteers and to study the effects of diet on the disease. 60 All twelve
received pardons and survived, but they were not permitted to leave the clinical
trial, even after suffering severe symptoms and begging to be released from it. 61
In California, between 1919 and 1922, hundreds of prisoners took part in a
testicular transplant experiment, designed to test whether lost male potency could
be reinvigorated. 62 During World War II great enthusiasm developed for prisoner
experimentation, and prisoners signed up for research trials in large numbers in
order to show their patriotism. 63 In New York scores of inmates volunteered for
daily doses of various drugs to assist the Anny in determining whether soldiers
could carry full workloads under the drugs' influence. 64 New Jersey supplied the
Army with willing participants for research regarding sleeping sickness, sand-fly
fever, and dengue fever. 65 In the Stateville Penitentiary in Illinois, more than 400
prisoners were included in a two-year-long study aimed at finding a cure for
malaria, and at the U.S. Penitentiary in Atlanta 600 inmates participated in other
malaria research. 66 As these experiments were developed, researchers began
utilizing informed consent forms to provide test subjects with information
regarding the trials so that investigators could claim that participants understood
the studies in which they enrolled and so that authorities could be absolved from
legal repercussions. 67 A considerable portion of participants in the malaria

55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.

See ENCYCLOPEDIA OF BIOETHICS, supra note I, at 2056.
See id.
See id.
See id.
See HORNBLUM, supra note 5, at 77.
See id. at 78.
See id. at 78-79.
See id. at 79.
See ENCYCLOPEDIA OF BIOETHICS, supra note I, at 2056.
See HORNBLUM, supra note 5, at 81.
See id.
See id. at 81, 83.
See id. at 82.

2000]

PRISONER PARTICIPATION IN CLINICAL TRIALS

483

studies received pardons as a reward for their bravery. 68
The most notorious large-scale medical experimentation in human history
was conducted by the Nazis during World War II. The elite of the German
medical community subjected innocent victims in concentration camps to "a
broad range of 'ghastly' and 'hideous"' experimentation. 69 In Buchenwald and
Natzweiler, numerous healthy inmates were involuntarily infected with yellow
fever, smallpox, typhus, cholera, and diphtheria germs that caused hundreds of
them to die. 70 In other camps Nazi doctors conducted experiments relating to
high altitude, malaria, freezing, mustard gas, bone transplantation, sea water,
sterilization, and incendiary bombs. 71
The full extent and inhumanity of the medical experimentation conducted by
Nazi doctors in concentration camps became public knowledge during the
Nuremberg Trials after World War 11. 72 The Nuremberg Trials were opened on
November 20, 1945 at the Palace of Justice in Nuremberg, Germany. 73 Twenty
three Nazi physicians were found guilty of "war crimes and crimes against
humanity," and seven of them were sentenced to death. 74 At the trials the defense
argued that the Nazis' research was no worse than "the wartime experiments in
the United States such as those carried out at the Joilet, Illinois, prison in which
treatments for malaria were sought by physicians who had to first infect the
volunteer prisoners with the disease." 75 These arguments failed, however,
because the prosecution focused on the fact that in the concentration camps
inmates had no choice regarding the torments to which they were subjected, and
in the United States prisoners volunteered to participate in clinical trials. 76
Japanese researchers also conducted barbarous experiments on prisoners in
Manchuria during World War 11. 77 The Japanese investigators, however, were
never tried, and their crimes remained hidden from public scrutiny for over
thirty-five years. 78 In exchange for silence, the Japanese agreed to share with the
American government the data they had gathered regarding biological warfare
through experimentation with Chinese captives. 79
As a result of the Nuremberg Trials, the Nuremberg Code was

See id.
!d. at 75.
See id.
See id. at 75, 77.
72. See Colleen M. McCarthy, Note, Experimentation on Prisoners: The Inadequacy of
Voluntary Consent, 15 NEW ENG. J. ON CR!M. & C!V. CONFINEMENT 55, 57 (1989).
73. See Bernard D. Meltzer, "War Crimes:" The Nuremberg Trial and the Tribuna/for the
Former Yugoslavia, 30 VAL. L. REv. 895,896 (1996).
74. See McCarthy, supra note 72, at 57 n.IO.
75. !d. (citing A.M. Capron, Human Experimentation, in I BIOLAW § 10, at 229 (1986)).
76. See id.
77. See id.
78. See id.
79. See id.
68.
69.
70.
71.
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promulgated. 80 The Code is included in the Nuremberg Military Tribunal's
decision in the case of United States v. Karl Brandt. 81 The Code features
ten points that delineate the circumstances under which medical
experimentation on human subjects is permissible. 82 During the latter part

80.
81.
82.
I.

See id. at 57.
See 5 ENCYCLOPEDIA OF BIOETHICS, supra note I, app. at 2763.
Nuremberg Code (1947). The full text of the Nuremberg Code is as follows:
The voluntary consent of the human subject is absolutely essential.

This means that the person involved should have legal capacity to give consent;
should be so situated as to be able to exercise free power of choice, without the
intervention of any element of force, fraud, deceit, duress, over-reaching, or
other ulterior form of constraint or coercion; and should have sufficient
knowledge and comprehension of the elements of the subject matter involved
as to enable him to make an understanding and enlightened decision. This
latter element requires that before the acceptance of an affirmative decision by
the experimental subject there should be made known to him the nature,
duration, and purpose of the experiment; the method and means by which it is
to be conducted; all inconveniences and hazards reasonably to be expected; and
the effects upon his health or person which may possibly come from his
participation in the experiment.
The duty and responsibility for ascertaining the quality of the consent rests
upon each individual who initiates, directs or engages in the experiment. It is
a personal duty and responsibility which may not be delegated to another with
impunity.
2.

The experiment should be such as to yield fruitful results for the good of
society, unprocurable by other methods or means of study, and not random and
unnecessary in nature.

3.

The experiment should be so designed and based on the results of animal
experimentation and a knowledge of the natural history of the disease or other
problem under study that the anticipated results will justify the performance of
the experiment.

4.

The experiment should be so conducted as to avoid all unnecessary physical
and mental suffering and injury.

5.

No experiment should be conducted where there is an a priori reason to believe
that death or disabling injury will occur; except, perhaps, in those experiments
where the experimental physicians also serve as subjects.

6.

The degree of risk to be taken should never exceed that determined by the
humanitarian importance of the problem to be solved by the experiment.
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of the Twentieth Century, prisoners have rarely, if ever, been involved in
clinical trials outside of the United States. 83
In the United States, however, medical research involving prisoners
continued for several decades after World War II. In 1953 testing on federal
prisoners included research regarding hepatitis, heart disease, intestinal
protozoan parasites, athlete's foot, and the common cold. 84 In the early 1950s
nearly 100% of participants in Phase I clinical trials across the United States
were prisoners, according to the former chief of clinical investigations for the
FDA, Dr. Alan B. Lisook. 85
The Ohio prison system was involved in some of the most dangerous and
controversial experiments ofthe mid-1950s. 86 The research was conducted in
conjunction with the Sloan Kettering Institute for Cancer Research and Ohio
State University's medical research department. 87 Inmates volunteered to be
injected with live cancer cells in both forearms. 88 Two weeks after the injection,
the affected area of one forearm would be surgically removed for study, while the
malignant cells remained in the other forearm for an indefinite period of time. 89
Medical experimentation in the 1950s was not limited to physical ailments.
At the Ionia State Hospital in Michigan, at least 142 inmates participated in
secret mind-control experiments for the CIA. 90 The CIA gave numerous "sexual

7.

Proper preparations should be made and adequate facilities provided to protect
the experimental subject against even remote possibilities of injury, disability,
or death.

8.

The experiment should be conducted only by scientifically qualified persons.
The highest degree of skill and care should be required through all stages of the
experiment of those who conduct or engage in the experiment.

9.

During the course of the experiment the human subject should be at liberty to
bring the experiment to an end if he has reached the physical or mental state
where continuation of the experiment seems to him to be impossible.

During the course of the experiment the scientist in charge must be prepared to
terminate the experiment at any stage, if he has probable cause to believe, in the
exercise ofthe good faith, superior skill and careful judgment required of him
that a continuation of the experiment is likely to result in injury, disability, or
death to the experimental subject.
Id at 2763-64.
83. See Schroeder, supra note 3, at 970; REPORT, supra note 2, at 3077.
84. See HORNBLUM, supra note 5, at 89-90.
85. See id. at 43.
86. See id. at 93.
87. See id.
88. See id.
89. See id.
90. See id. at 95.
10.
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psychopaths" LSD and marijuana in order to "test the effectiveness of certain
medication in causing individuals to release guarded information under
interrogation. " 91
Biomedical experimentation on prisoners could be extremely lucrative for
doctors. Dr. Austin R. Stough, an Oklahoma physician, is estimated to have
earned approximately $1 million a year by selling blood plasma extracted from
volunteer prisoners in Oklahoma, Arkansas, and Alabama and by using the
prisoners for drug testing. 92 His customers included Bristol-Myers, Merck,
Sharp & Dohme, Upjohn, Lederle, and American Home Products. 93
Throughout the 1960s, in fact, drug companies competed for access to prison
populations. 94 In 1964, Upjohn and Parke-Davis contributed over a half million
dollars to build a state of the art laboratory inside the State Prison of Southern
Michigan at Jackson, which was the largest walled penitentiary in the world and
housed 4100 inmates. 95 Inmates were trained to run the tests in prison labs
themselves and were paid between $.35 and $1.25 per day, a small fraction of
what employees doing such work would earn in a non-prison environment. 96
Medical experimentation in prisons continued throughout the 1960s and early
1970s. 97 In 1969 eighty-five percent of all new drugs were tested on prisoners
in forty-two prisons. 98 As late as 1975 at least 3600 prisoners in the United
States were used by drug companies as the first humans on whom the safety of
new medication was tested. 99 The federal government, through the Atomic
Energy Commission, funded a decade-long radiation study on inmates in Oregon
and Washington State prisons. 100 The experiments were designed to determine
how much radiation U.S. astronauts could tolerate during space flights. 101
Prisoners volunteered for the testing and received small monetary payments, but
were required to undergo radiation exposure to their testicles at rates equivalent
to approximately twenty diagnostic x-rays. 102 Test subjects suffered painful,
lasting effects, and, according to some estimates, almost half of them have since
died. 103 From 1970 to 1975 five agencies of the federal government utilized
prison inmates in 125 biomedical experiments and nineteen behavioral research
studies. 104

91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.

!d.
See
See
See
See
See
See
See
See
See
See
See
See
See

id. at 97.
id.
id. at l03.
id.
id.
id. at 108.
Schroeder, supra note 3, at 971.
ENCYCLOPEDIA OF BIOETHICS, supra note 1, at 2056-57.
HORNBLUM, supra note 5, at 107.
id.
id.
id. at 108.
ENCYCLOPEDIA OF BIOETHICS, supra note 1, at 2056.
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In Petersburg, Virginia, Dr. John L. Sever of the National Institutes ofHealth
conducted a rubella project, exposing prisoners to the disease for sixteen weeks
at a time. 105 Inmates earned twenty dollars for their participation. 106 In California
and Arizona prisoners were involved in weightlessness experiments for the
National Aeronautic and Space Administration. 107 Prisoners were required to
remain in bed at all times, some for over six months. 108 In addition, some were
placed in compression suits and were forced to endure repeated blood and
calcium tests and radioactive isotope injections. 109 Subjects were paid fifty
dollars per month and an additional fifty dollars for completing the study. 110
They also signed informed consent forms, and these, unlike their predecessors,
provided inmates with some degree of protection by stating that the consent
forms "shall not be construed as a release ofNASA from any future liability." 111
In Acres of Skin, Allen M. Hornblum wrote an expose of the twenty-year
testing program at Philadelphia's Holmesburg Prison. The program was run by
Dr. Albert M. Kligman, a University of Pennsylvania dermatology professor. 112
Hornblum is particularly critical of three biomedical experiments conducted
by Kligman at the prison. First, in conjunction with the Army, he tested a mindaltering substance known as EA 3167 on prisoners in an effort to determine
whether it should be added to the Army's chemical warfare stock. 113 Inmates
suffered confusion and hallucinations for up to three weeks. 114 In addition,
Kligman tested radioactive isotopes at the prison despite having little education
or experience in radioactive medicine. 115 Hornblum alleges that Kligman made
various misrepresentations to the U.S. Atomic Energy Commission in order to
obtain a required license from the federal government. 116 The third experiment
denounced by Hornblum is one conducted for Dow Chemical Corporation,
involving dioxin, a component of Agent Orange. 117 According to the book,
Kligman subjected several prisoners to 7500 micrograms of the toxic substance,
468 times the dosage he was instructed to administer by Dow Chemicals. 118
Hornblum observes in his book that "[t]he Holmesburg experiments took
place before the rise of investigative journalism, and the media, the government,

I 05.
106.
107.
108.
109.
110.
111.
112.
remover,
113.
114.
115.
116.
117.
118.

See HORNBLUM, supra note 5, at I 08.
See id.
See id.
See id. at 109.
See id.
Seeid.at108.
/d. at 109.
See id. at xix-xx, 35. Kligman is the inventor of Retin-A, the acne cream and wrinkle
which he tested on Holmesburg prisoners. See id. at 214.
See id. at 127-30, 137, 141-43.
See id. at 129.
See id. at 149-61.
See id.
See id. at 163-83.
See id. at 169.
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and the public in general, neither knew nor cared about the events occurring daily
within the walls ofthe old city jail." 119 That indifference would vanish in the
1970s.
Ill. THE OUTCRY AGAINST EXPERIMENTATION ON PRISONERS
AND ITS CONSEQUENCES

Concern regarding the mistreatment of medical research subjects in the
United States developed in the early 1970s, largely as a result of publicity
concerning the Tuskegee syphilis study. 120 The Tuskegee study was conducted
from the 1950s until the beginning of the 1970s and was designed to study the
effects of untreated syphilis in a group of African American men. 121 The
researchers professed to treat the patients, but never divulged to them that they
were not being provided with the easily available and fully effective cure 122 of
penicillin. 123 The subjects thus continued to suffer from the debilitating illness
while believing that they were receiving adequate care. 124
The Senate held subcommittee hearings in 1973 and subsequently established
the National Commission for the Protection of Human Subjects in Biomedical
and Behavioral Research through the National Research Act of 1974. 125 The
National Commission operated between 1974 and 1978. 126 In 1976 the
Commission recommended to the Secretary of the Department of Health,
Education and Welfare ("HEW") (now "DHHS") that the government declare a
moratorium on funding and approving prisoner studies until any prison that
allowed inmate experimentation met at least minimum criteria to protect inmate
subjects. 127 HEW published regulations for prisoner protection in clinical trials
in 1978. 128 Although DHHS modified the regulations addressing biomedical
research when it succeeded HEW, it retained the sections relating to prisoners. 129
In general, DHHS regulations apply to any research involving human subjects
that is conducted, supported, or regulated by any federal department or agency. 130
DHHS regulations are designed to limit the circumstances in which
researchers may include prisoners in their studies and to provide adequate

119.
120.
121.
122.
123.
124.
125.
126.
(1995).
127.
81.
128.
129.
130.

/d. at 242.
See McCarthy, supra note 72, at 58.
See WILLIAM J. CURRAN ET AL., HEALTH CARE LAW AND ETHICS 276 (5th ed. 1998).
See id.
See THE BANTAM MEDICAL DICTIONARY 424 (rev. ed. 1990).
See CURRAN ET AL., supra note 121, at 276.
See Pub. L. 93-348, 88 Stat. 342, § 201; McCarthy, supra note 72, at 58-59.
See BARUCH A. BRODY, ETHICAL ISSUES IN DRUG TESTING, APPROVALAND PRICING 103

See ENCYCLOPEDIAOFBIOETHICS, supra note 1, at 2056; REPORT, supra note 2, at 3079See generally 45 C.F.R. § 46.301 (1998).
See McCarthy, supra note 72, at 59.
See 45 C.F.R. § 46.l01(a).
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protection to inmate subjects. The regulations recognize that prisoners living in
a harsh prison setting may be coerced into accepting risks that free citizens would
not and that investigators may be tempted to utilize a "captive" group to undergo
biomedical studies that would not be tolerated by civilians who are not
incarcerated. 131
The regulations impose special requirements and duties upon IRBs assessing
clinical trials that involve prisoners. An IRB reviewing such research must
include at least one prisoner or prisoner advocate, and a majority of its members
may not be otherwise associated with the prison at issue. 132
The IRB must ensure that the advantages that the prisoners enjoy through
participation in the trial with respect to living conditions, healthcare, food,
amenities, and potential earnings are not so great as to render the inmate unable
to weigh the risks ofthe study against its benefits in the prison environment. 133

131. See Eileen Kelly, Expanding Prisoners' Access to AIDS-Related Clinical Trials: An
Ethical and Clinical Imperative, 75 THE PRISON JOURNAL 48, 57 (1995).
132. See 45 C.F.R. § 46.304. The provision reads in relevant part as follows:
In addition to satisfying the requirements in § 46.107 of this part, an Institutional
Review Board, carrying out responsibilities under this part with respect to research
covered by this subpart, shall also meet the following specific requirements:
(a)

A majority of the Board (exclusive of prisoner members) shall have no
association with the prison(s) involved, apart from their membership on the
Board.

(b)

At least one member of the Board shall be a prisoner, or a prisoner
representative with appropriate background and experience to serve in that
capacity, except that where a particular research project is reviewed by more
than one Board only one Board need satisfy this requirement.

/d.

133.
(a)

See id. § 46.305(a)(2). The regulation found at 45 C.F.R. § 46.305(a) reads as follows:
In addition to all other responsibilities prescribed for Institutional Review
Boards under this part, the Board shall review research covered by this subpart
and approve such research only if it finds that:

( 1)

The research under review represents one of the categories of research
permissible under§ 46.306(a)(2) [see infra note 139];

(2)

Any possible advantages accruing to the prisoner through his or her
participation in the research, when compared to the general living
conditions, medical care, quality of food, amenities and opportunity for
earnings in the prison, are not of such a magnitude that his or her ability to
weigh the risks of the research against the value of such advantages in the
limited choice environment of the prison is impaired;

(3)

The risks involved in the research are commensurate with risks that would
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In addition, the risks involved in the trial must be equivalent to those that would
be acceptable to non-inmate volunteers, 134 and the procedures implemented for
the selection of participants should be fair and not subject to arbitrary
intervention by prison officials or prisoners. 135 Information provided to prisoners
for purposes of informed consent must be articulated in language that is
comprehensible to the inmate population. 136 In addition, Parole boards may not
consider prisoner participation in clinical trials when making parole decisions,
and prisoners must be informed of this fact. 137 Finally, adequate follow-up care
must be provided, when appropriate, to participants. 138
The regulations limit inmate participation in clinical investigations to the
following: ( 1) studies of the possible causes, effects, and processes of
imprisonment and criminal behavior so long as the research involves only
minimal risk and inconvenience to the subject; (2) studies of prisons as
institutional entities or of inmates as incarcerated individuals so long as the
research involves only minimal risk and inconvenience to the subject; (3)
research on particular conditions affecting prisoners as a class so long as the
study is approved by the Secretary; and (4) research involving a treatment likely

be accepted by nonprisoner volunteers;
(4)

Procedures for the selection of subjects within the prison are fair to all
prisoners and immune from arbitrary intervention by prison authorities or
prisoners. Unless the principal investigator provides to the Board
justification in writing for following some other procedures, control subjects
must be selected randomly from the group of available prisoners who meet
the characteristics needed for that particular research project;

(5)

The information is presented in language which is understandable to the
subject population;

(6)

Adequate assurance exists that parole boards wiii not take into account a
prisoner's participation in the research in making decisions regarding parole,
and each prisoner is clearly informed in advance that participation in the
research will have no effect on his or her parole; and

(7)

Where the Board finds there may be a need for follow-up examination or
care of participants after the end of their participation, adequate provision
has been made for such examination or care, taking into account the varying
lengths of individual prisoners' sentences, and for informing participants of
this fact.

/d.

134.
135.
136.
137.
138.

See
See
See
See
See

id.
id.
id.
id.
id

§ 46.305(a)(3).
§ 46.305(a)(4).
§ 46.305(a)(5).
§ 46.305(a)(6).
§ 46.305(a}(7).
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to benefit the prisoners themselves. 139 If a prisoner might be assigned to a
placebo control arm, the study can proceed only with the Secretary's approval. 140
The FDA, an agency ofDHHS, 141 published its own proposed regulations in
1980. 142 The regulations were substantially the same as those issued by

139.
(a)

See id. § 46.306(a)(2). The regulation reads in relevant part:
Biomedical or behavioral research conducted or supported by DHHS may
involve prisoners as subjects only if:

(I)

The institution responsible for the conduct of the research has certified to the
Secretary that the Institutional Review Board has approved the research
under§ 46.305 of this subpart; and

(2)

In the judgment of the Secretary [Health and Human Services] the proposed
research involves solely the following:
(i)

Study of the possible causes, effects, and processes of incarceration,
and of criminal behavior, provided that the study presents no more
than minimal risk and no more than inconvenience to the subjects;

(ii)

Study of prisons as institutional structures or of prisoners as
incarcerated persons, provided that the study presents no more than
minimal risk and no more than inconvenience to the subjects;

(iii) Research on conditions particularly affecting prisoners as a class (for
example, vaccine trials and other research on hepatitis which is much
more prevalent in prisons than elsewhere; and research on social and
psychological problems such as alcoholism, drug addiction and sexual
assaults) provided that the study may proceed only after the Secretary
has consulted with appropriate experts including experts in penology
medicine and ethics, and published notice, in the Federal Register, of
his intent to approve such research; or
(iv) Research on practices, both innovative and accepted, which have the
intent and reasonable probability of improving the health or well-being
of the subject. In cases in which those studies require the assignment
of prisoners in a manner consistent with protocols approved by the
IRB to control groups which may not benefit from the research, the
study may proceed only after the Secretary has consulted with
appropriate experts, including experts in penology medicine and ethics,
and published notice, in the Federal Register, of his intent to approve
such research.
I d.
140.
141.
142.

See id. § 46.306(a)(2)(iv).
See Kelly, supra note 131, at 57.
See Schroeder, supra note 3, at 984-85.
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DHHS. 143 Nevertheless, on July 29, 1980 inmates in the Michigan State
Penitentiary at Jackson filed a lawsuit challenging the proposed FDA
regulations. 144 On November 12, 1980, the Upjohn Company, the primary
sponsor of drug research at Jackson, intervened as a plaintiff in the case. 145 The
plaintiffs alleged that the FDA's proposed ban on prisoner participation in
nontherapeutic drug experimentation violated the Equal Protection and Due
Process clauses of the Fifth Amendment. 146 With the lawsuit pending, the FDA
stayed the effective date of its regulations. 147 The FDA has never removed its
stay or reproposed its regulations. 148
Existing federal regulations provide significant protection for prisoners
participating in clinical trials. 149 Prisoner participation must be informed and
voluntary and cannot pose more than minimal risk to the research subject.
Despite the many safeguards implemented by DHHS, few inmates have access
to clinical trials. 150 According to a survey conducted by the American
Correctional Health Services Association, bioemedical research involving
inmates is prohibited in twenty-two states. 151 Relatively few research institutions
have accepted prisoners in clinical trials in recent years. These include facilities
in Colorado, Connecticut, Maryland, New York, Texas, and Virginia. 152
In light of history, a concern may exist that individuals cannot, under any
circumstances, be adequately protected in a prison setting and that any
biomedical experimentation will lead to a violation of the prisoners' legal and
moral rights. While it is wise for researchers to be mindful of the sensitive

143. See Kelly, supra note 131, at 59.
144. See Fante v. Department of Health and Human Services, Civil Action No. 80-72778,
(E.D. Mich. filed July 29, 1980), cited in 46 Fed. Reg. 35085 (1981).
145. See id; Schroeder, supra note 3, at 986.
146. See Fante, 46 Fed. Reg. at 35085; Schroeder, supra note 3, at 986.
147. See Kelly, supra note 131, at 56.
148. See id
149. A recent statement issued by the Office of the Inspector General of the U.S. Department
of Health and Human Services is highly critical of the institutional review board system. According
to the report, the regulations are inadequately implemented and human subjects are insufficiently
protected by IRBs. However, the report did not focus specifically on review of protocols involving
prisoners, a process that is subject to higher standards. See OFFICE OF INSPECTOR GENERAL, U.S.
DEP'T OF HEALTH & HUMAN SERVICES, INSTITUTIONAL REVIEW BOARDS: A TIME FOR REFORM
( 1998); see also discussion infra Part V .B. Nevertheless, while the regulations themselves provide
ample protection for prisoners, some IRBs may be inconsistent in applying the guidelines. The IRB
system may therefore need to undergo scrutiny and improvement in order to ascertain that, in
practice, prisoners consistently enjoy the benefits of the regulatory safeguards.
150. See Schar, supra note 12, at 1185 n.235.
151. See Kelly, supra note 131, at 58 (citing Kathryn Duke, Achieving Balance: Biomedical
Research and Inmates, CORHEALTH, Falll993, at I, 2).
152. See id. at 59. GARY L. STEIN & LINDA D. HEADLEY, NORTH JERSEY COMMUNITY
RESEARCH INITIATIVE, PRISONERS WITH HIV: GUIDELINES FOR IMPLEMENTING CLINICAL TRIALS IN
CORRECTIONAL SETTINGS 7 (July 1995).
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circumstances of prisoners, it is also unwise to exclude inmates from all clinical
trials. Denying seriously ill prisoners access to experimental treatments may
constitute an equivalent violation of prisoner rights and is similarly problematic
in moral and legal terms. The next section will focus on the potential
constitutional issues implicated in biomedical experimentation involving
prisoners.
IV. ANALYSIS OF THE CONSTITUTIONAL RIGHTS OF PRISONERS AS THEY
RELATE TO BIOMEDICAL EXPERIMENTATION

A. While Irresponsible Clinical Research May Violate Prisoners '
Eighth Amendment Rights, Denial of Potentially Life-Saving
Experimental Treatment to Prisoners Also Constitutes
Unconstitutional Cruel and Unusual Punishment
1.
Eighth Amendment Overview.-The Eighth Amendment to the
Constitution of the United States prohibits the infliction of "cruel and unusual
punishment." 153 The Supreme Court originally construed the Eighth Amendment
as only precluding punishments oftorture and unnecessary cruelty 154 or sentences
that are grossly disproportionate to the crime committed. 155 The Supreme Court
subsequently broadened its interpretation of the Eighth Amendment and
determined that it applies to the treatment inmates receive while incarcerated, 156
including improper medical treatment. 157 The Amendment is understood to
embody "broad and idealistic concepts of dignity, civilized standards, humanity,
and decency .... " 158
Nevertheless, it is not easy for prisoners to prevail in Eighth Amendment
cases. An inmate alleging an Eighth Amendment violation must establish a grave
deprivation of rights to which prison officials have reacted with deliberate
indifference. 159 In determining whether a punishment violates the Eighth

153. U.S. CONST. amend. VIII. The text provides that "[e]xcessive bail shall not be required,
nor excessive fines imposed, nor cruel and unusual punishment inflicted." !d.
154. See Wilkerson v. Utah, 99 U.S. 130 (1878) (holding that death by firing squad is not
cruel and unusual punishment).
155. See Weems v. United States, 217 U.S. 349,382 (1910). In Weems the Court held that
the Eighth Amendment's cruel and unusual punishment clause was "progressive, and is not fastened
to the obsolete, but may acquire meaning as public opinion becomes enlightened by a humane
justice." !d. at 378. See also Samantha A. Moppett, Case Comment, Constitutional
Law-Extending Eighth Amendment Protections to Prisoners Involuntarily Exposed to
Unreasonable Levels ofEnvironmental Tobacco Smoke-Hel!ing v. McKinney, 28 SUFFOLK U. L.
REv. 200,202 (1994).
156. See Helling v. McKinney, 509 U.S. 25, 31 (1993); Moppett, supra note 155, at 202.
157. See Estelle v. Gamble, 429 U.S. 97, 106 (1976).
158. Jackson v. Bishop, 404 F.2d 571,579 (8th Cir. 1968)(summarizingthe Supreme Court's
cases and concluding that the limits of the Eighth Amendment are "not easily or exactly defined").
159. See Gamble, 429 U.S. at I 06 ("In order to state a cognizable claim, a prisoner must
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Amendment, the Supreme Court has assessed the challenged punitive measure
in light of the "evolving standards of decency that mark the progress of a
maturing society." 16° Furthermore, the Court has found that deliberate
indifference "entails something more than mere negligence ... [but] something
less than acts or omissions for the very purpose of causing harm or with
knowledge that harm will result." 161 In order to establish a deliberate
indifference claim based on improper medical treatment, an inmate must show
that prison officials (1) were aware ofthe individual's serious medical need; and
(2) disregarded, ignored, or refused to provide the inmate with treatment for that
need. 162
If an Eighth Amendment violation arises not from the acts of particular
prison officials but from a prison policy, a different test, first articulated by the
Supreme Court in 1987 in Turner v. Safley, 163 will be applied. In Safley, the
Court held that "when a prison regulation impinges on inmates' constitutional
rights, the regulation is valid if it is reasonably related to legitimate penological
interests." 164 In assessing the reasonableness of a regulation, the court must
consider the following four factors:
(1) 'there must be a "valid, rational connection" between the prison
regulation and the legitimate governmental interest put forward to justify
it;' (2) the court should determine whether there are alternative means
of exercising the constitutional right that remain open to the inmates; (3)
the court is to consider the impact that accommodation of the asserted
constitutional right will have on guards, other inmates, and on the
allocation of prison resources; and (4) the court should assess whether
there are ready alternatives to the prison regulation-the absence of such
ready alternatives suggests that the regulation is reasonable while their
existence may be evidence of the opposite. 165

2. Bailey v. Lally.-The case of Bailey v. Lally 166 provides a uniquely
thorough analysis of an Eighth Amendment challenge to the inclusion of prison
inmates in clinical trials. In Bailey, state prisoners brought a class action under
42 U .S.C. § 1983 alleging that prisoners who participated in clinical
investigations at the Maryland House of Correction's medical research unit had

allege acts or omissions sufficiently harmful to evidence deliberate indifference to serious medical
needs.").
160. Trop v. Dulles, 356 U.S. 86, 101 (1958).
161. Farmer v. Brennan, 511 U.S. 825, 835 (1994).
162. See id. at 837.
163. 482 U.S. 78 (1987). In Safley inmates challenged two regulations promulgated by the
Missouri Division of Corrections. The Court upheld the regulation concerning inmate-to-inmate
correspondence but found the inmate marriage regulation to be invalid.
164. !d. at 89. See also Lewis v. Casey, 518 U.S. 343, 361 (1996).
165. Walker v. Sumner, 917 F.2d 382, 385 (9th Cir. 1990)(quoting Safley, 482 U.S. at 9091).
166. 481 F. Supp. 203 (D. Md. 1979).
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suffered violations of their constitutional rights to due process, privacy, and
protection against cruel and unusual punishment. 167 After careful consideration
and lengthy discussion, the court ruled against the plaintiffs.
A recitation of the facts is important to understanding the court's analysis
and thus, will be provided in some detail. The Maryland House of Correction
("MHC") was opened in 1879 and was designed to house approximately 1100
inmates. 168 During the early 1970s the inmate population ranged from 1498 to
1617, and many cells designed for only one person housed two occupants at a
time. 169 Until1976, hot water was unavailable to prisoners. 170 During the winter,
inmates suffered from the cold because the prison's heating system was sorely
inadequate, and in the summer months, the facility was very hot. 171 A large
percentage of prisoners had no work, educational, or vocational activities and
spent between sixteen and seventeen hours per day in their cells. 172 Those with
jobs earned between $.63 and $1.46 per day, with the vast majority earning under
$1.1 0 a day. 173
A medical research unit was established at the MHC by doctors from the
University of Maryland School of Medicine, and research involving prisoners
commenced in 1958. 174 Prisoners participating in clinical trials were paid two
dollars per day, including Saturdays and Sundays, and additional payments were
made if the prisoner underwent particular medical procedures. 175 Approximately
one third of the participants lived full-time in a designated section of the medical
research unit that, unlike the rest of the prison, had hot water, color television,
and three separate bathroom facilities. 176 The patients could retain their jobs and
enjoy the income earned from the medical research as a supplement to other
earnings. 177 Participation in clinical trials, however, had no impact on parole
decisions. 178 This fact was disclosed to some, but not all of the inmates. 179
Prisoners learned of the medical research unit via word of mouth or from an
application that some were given when they entered MHC and that was also
published in the prison newspaper. 180 Inmates wishing to be included in the
medical experimentation were required to complete the application, which

167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.

Seeid.
See id.
See id.
See id.
See id.
See id.
See id.
See id.
See id.
See id.
See id.
See id.
See id.
See id.

at 205.

at 205-06. Prisoners working in the laundry earned $2.22 per day. See id.
at 206.

at 209-10.
at 207.
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included detailed information regarding the research. 181 When a study was to be
commenced, all applicants would be gathered as a group and addressed by a
nurse or a doctor, who explained the reason for and nature of the experimentation
as well as its possible risks. Inmates who again expressed interest in participation
underwent a physical examination and were given repetitive oral explanations in
layman's terms, with opportunities for questions and answers. 182
Those who were ultimately accepted as participants in the studies were given
additional verbal data about the research and were told that they could withdraw
at any time. 183 Many in fact did withdraw both before and during various stages
of experimentation. 184 Prisoners were also asked to sign a written consent
form.1s5
The medical research unit at MHC conducted nontherapeutic studies of
various infectious diseases including malaria, cholera, shigella, viral diarrhea,
influenza, typhoid, e. coii, and rhinovirus. 186 Nontherapeutic studies are those
that do not provide any direct medical benefit to the patient but seek to produce
general knowledge about a particular disorder or condition. 187 All of the diseases
investigated, with the exceptions of the common cold and the flu, had known
cures. 188 Approximately fourteen percent of the prisoners incarcerated at MHC
from 1971 to 1975 participated in the medical studies. 189
The plaintiffs alleged in their lawsuit that the poor prison conditions, their
idleness, and the salary, which far exceeded earnings from other prison jobs,
rendered their participation in the clinical trials coerced and consequently
resulted in violations of their Eighth Amendment and other constitutional
rights. 190 The Eighth Amendment claim revolved around the question of whether
individuals incarcerated in a prison setting can give truly meaningful consent and
rationally choose to volunteer for the trial with a full understanding of both its
benefits and its risks. 191
The Bailey court found that the prisoners were adequately informed in light
of the numerous verbal explanations and the written consent forms they
received. 192 The plaintiffs' strongest allegations were thus rooted in the issue of
voluntariness. The plaintiffs argued that the overcrowded and extremely
uncomfortable conditions of regular institutional life at MHC caused them to
over-value the potential earnings and hours away from their cells and deprived
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id. at 208.
id. at 210.
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id. at 212 n.15.
45 C.F.R. § 46.406 (1998).
Bailey, 481 F. Supp. at 212.
id. at 220.
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id. at 219-20.
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them of the ability to make a meaningful decision. 193
The court rejected the plaintiffs' claims. It noted that in fact a very small
minority of prisoners (only fourteen percent) found the medical research
programs appealing and that there was a constant shortage ofvolunteers. 194 In
addition, the court noted the following:
Prisoners at the MHC were not subject to physical abuse, or confined in
segregated cells, or restricted to meagre [sic] diets, until they consented
to participate in MRU studies. Prisoners were not pressured to
participate. To the contrary, prisoners had a viable choice and, even
after choosing to participate, had the option to withdraw from the
medical studies. 195
The court decision also emphasized that the experiments did not create a danger
to the subjects' lives or future health and that the risks of temporary discomfort
were fully disclosed to the inmates. 196 Finally, the court focused upon the fact
that participation in the clinical studies did not facilitate the inmates' release
from MHC, and thus, early parole was not an incentive for enrollment. 197 The
court found that the plaintiffs' Eighth Amendment claim failed because the
defendant's conduct was not "incompatible with evolving standards of
decency" 198 and did not subject them to undue coercion. 199
The medical research in the Bailey case was conducted before the DHHS
issued its regulations for prisoner research in 1978. 200 Today prisoners involved
in clinical trials would enjoy far greater protection than that available to the
plaintiffs in the Bailey case. 201 Moreover, the experimentation conducted in
Bailey, which was found not to violate any constitutional rights, would be
prohibited by DHHS regulations because it was nontherapeutic, did not benefit
the subjects, and did not fall into any ofthe categories of permissible research. 202
In light of contemporary regulatory safeguards and the restrictions placed on
investigators conducting research involving prisoners, it is extremely unlikely
that prisoner participants would suffer a violation of Eighth Amendment rights
in the context of a clinical trial that complies with federal guidelines.
3. Seriously Ill Prisoners May Greatly Benefit from Experimental
Therapies .-In many instances, experimental treatments provided through
clinical trials constitute last chance therapies for desperately ill patients who

193.
194.
195.
196.
197.
198.
199.
200.
201.
202.

See id. at 220.
See id.
!d.
See id. at 221.
See id.
/d. at219.
See id. at 221.
See McCarthy, supra note 72, at 59.
See discussion supra Part III.
See 45 C.F.R. § 46.306(a)(2) (1998).
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cannot be cured by conventional medicine. 203 In the prison setting, where a
significant percentage of inmates are mv positive, experimental treatments
could benefit many individuals and save many lives. 204 Experimental treatments
may also be sought by inmates suffering from cancer/05 hepatitis, 206
tuberculosis, 207 and other diseases.
HIV is one of the predominant health problems in U.S. prisons. 208 While
HIV had an incidence rate of eighteen cases per 100,000 in the general
population in 1992, the rate among prisoners was estimated to be 362 per
100,000 that same year. 209 Accounting for up to two-thirds of all inmate deaths
in some states, AIDS is the leading killer in correctional facilities. 210 A 1992-93
survey conducted by the National Institutes of Justice ("NIJ") and the federal
Centers for Disease Control and Prevention ("CDC") revealed a total of more
than 11,500 AIDS cases and almost 3500 AIDS-related deaths among prisoners
in state, federal, county, and large city correctional facilities. 211 The New Jersey
Department of Health estimates that almost nine percent of adult male inmates
and more than fourteen percent of adult female inmates are infected with HIV. 212
The Department further estimates that among prisoners with a history of illegal
drug use, forty percent of the men and 42.6% of the women are HIV positive. 213
Inmates who are mv positive are highly susceptibletotuberculosis. 214 From
1976 to 1978, tuberculosis had an incidence rate of15.4 per 100,000 among New
York state prisoners. 215 By 1992 there was a 1300% increase to a rate of 189 per
100,000. 216
Despite significant advances in the treatment of AIDS, contemporary
treatment modalities offer only limited relief to patients. 217 Participation in
clinical trials can provide inmates with access to promising experimental
drugs. 218 At times, experimental protocols may constitute the only meaningful

203. See Angela R. Holder, Funding Innovative Medical Treatment, 57 ALB. L. REv. 795,
795 (1994).
204. See Kelly, supra note 131, at 48.
205. See Holder, supra note 203, at 795-96.
206. See 45 C.F.R. § 46.306(a)(2)(iii).
207. See Schar, supra note 12, at 1156.
208. See James W. Marquart et al., Health Condition and Prisoners: A Review of Research
and Emerging Areas of Inquiry, 77 THE PRISON JOURNAL 185 (1997).
209. See id.
210. See Kelly, supra note 131, at 49.
211. See STEIN & HEADLEY, supra note 152, at 4.
212. See id.
213. See id.
214. See Curtis Prout, Clinical Challenges in the Climate ofPrison, 107 TRANSACTIONS OF
THE AM. CLIMATOLOGICAL AND CLINICAL ASS 'N 287, 290 ( 1995).
215. See id.
216. See id.
217. See STEIN & HEADLEY, supra note 152, at 4.
218. See id. at 9. Since prisoners are precluded from participating in placebo-controlled
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opportunity for a prisoner to receive treatment. 219 Biomedical research may also
provide inmates with the moral satisfaction of contributing to the advancement
of AIDS research 220 and with the opportunity "to give something back to society,
to redeem, atone, and reconcile." 221 Several commentators have urged the
inclusion of prisoners in clinical trials relating to HIV and AIDS 222 and in other
studies that might benefit prisoners. 223
Regulations prohibiting seriously ill prisoners from participation in clinical
trials in all cases, including those in which their exclusion results in the denial
of potentially life-saving therapy, are vulnerable to constitutional attack.
Although no court has rendered a decision regarding this issue, a viable
constitutional argument can be made that prisoners with life-threatening illnesses
that cannot be otherwise treated have a right to participate in biomedical research
that complies with federal regulations. 224
4. The Eighth Amendment Right to Medical Treatment.-The Supreme Court
has determined that the government is obligated to provide medical care for
prisoners because incarcerated individuals cannot independently obtain
healthcare. 225 The Court has further stated that "deliberate indifference to serious
medical needs of prisoners constitutes the 'unnecessary and wanton infliction of
pain,' proscribed by the Eighth Amendment." 226 A prisoner may bring a cause
of action for an Eighth Amendment violation under 42 U.S.C. § 1983 if

studies unless the research is approved by the Secretary, prisoners will rarely be deprived of active
therapy as research subjects. Generally, those assigned to the control arm of the study will be given
standard therapy from which they are likely to benefit.
219. See Dale L. Moore, An IRB Member's Perspective on Access to Innovative Therapy, 57
ALB. L. REV. 559, 571-72 (1994) ("[A] significant component of the treatment available to AIDS
patients is provided through clinical research trials of new drugs or drug combinations.").
220. See STEIN & HEADLEY, supra note 152, at 9.
221. Richard W. Garnett, Why Informed Consent? Human Experimentation and the Ethics
of Autonomy, 36 CATH. LAW. 455,481 (1996).
222. See, e.g, STEIN & HEADLEY, supra note 152, at 9; Kelly, supra note 131, at 55; Moore,
supra note 219, at 571-72.
223. See, e.g, Prout, supra note 214, at 291. Prout argues that "[t]here is a crying need for
genetic studies" because significant evidence indicates that many prisoners have fathers and
grandfathers who were also incarcerated. Id Prout admits, however, that this proposal is
controversial because of"fears ofbreaches of confidentiality, manipulation of the data, and possible
political implications having to do with race and ethnicity." /d. at 291-92.
224. Several commentators have argued that the Eighth Amendment requires that sexual
offenders who request castration as therapy for their paraphiliac disabilities be provided with the
surgical treatment once proper medical evaluation and informed consent have been obtained. Their
thesis features several parallels to the arguments made in this Article. See William Winslade et al.,
Castrating Pedophiles Convicted of Sex Offenses Against Children: New Treatment or Old
Punishment?, 51 SMU L. REV. 349 (1998).
225. See Estelle v. Gamble, 429 U.S. 97, 103 (1976).
226. /d. at 104 (quoting Gregg v. Georgia, 428 U.S. 153, 171 (1976)).
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authorities show deliberate indifference to his or her serious illness or injury. 227
In Helling v. McKinney 28 a prisoner alleged that prison authorities had
subjected him to cruel and unusual punishment by assigning him to a cell with
an inmate who smoked five packs of cigarettes a day, and thus the officials had
jeopardized his health. 229 The complaint further asserted that cigarettes were sold
to inmates in the prison and that nonsmoking inmates were not informed of the
health hazards associated with breathing smoke produced by their cellmates. 230
The Supreme Court held that the Eighth Amendment's protection against
deliberate indifference to a prisoner's health problems extends not only to current
serious health problems, but also to conditions that threaten to cause health
problems in the future. 231 Consequently, the prisoner stated a cause of action
under the Eighth Amendment when he alleged that prison officials had, with
deliberate indifference, exposed him to levels of environmental tobacco smoke
that created an unreasonable risk of serious damage to his health in the future. 232
In order to obtain injunctive relief, however, the plaintiff would be required on
remand to prove both an objective and a subjective element. 233 First, he would
have to prove that society considers the risk of which he complains "to be so
grave that it violates contemporary standards of decency to expose anyone
unwillingly to such a risk." 234 Second, the inmate would be required to establish
the subjective factor that prison officials had shown deliberate indifference to the
hazards posed to his health. 235 To do so, the plaintiff would need to focus upon
the officials' current attitudes and conduct. 236
If exposure to environmental tobacco smoke can constitute an Eighth
Amendment violation, it stands to reason that the denial of experimental therapy
to an incarcerated person who is seriously ill could also rise to the level of a
constitutional violation. If a clinical trial is available for a prisoner who suffers
from AIDS or another serious illness and prison officials deny the inmate access
to the trial, the inmate. might be able to establish a valid cause of action. The
prisoner would have to show that failure to allow him access to the available
clinical study is so grave that it violates contemporary standards of decency. 237
If the illness at issue is a terminal one, such as cancer or AIDS, for which
conventional treatments have failed, this element may not be difficult to
establish. In addition, the prisoner will have to prove that the prison officials had
shown deliberate indifference to his medical condition by preventing him from
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See id. at 105.
509 u.s. 25 (1993).
See id. at 28.
See id.
See id. at 33.
See id. at 35.
See id. at 36.
!d.
See id.
See id.
See id.
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participating in the biomedical research. 238 Success in establishing this element
will depend upon the prison officials' reasoning and motivations. 239 However,
under Helling, the prisoner will not be required to prove that exclusion from the
clinical trial posed an immediate risk of physical deterioration, but rather, only
that his or her future health may be jeopardized.240 This principle is important
for prisoners who are HIV positive since HIV patients may be asymptomatic or
minimally symptomatic for many years. However, their future prognosis will
depend upon the therapy that they receive throughout the course of the disease,
and therapy for mv patients often includes experimental drug combinations. 241
If a state implements a regulation that prohibits prisoner participation in
clinical trials, as many states have done, the Safley test would be used to evaluate
any constitutional claim asserted by a prisoner. 242 If the prisoner could establish
that the regulation denying access to research studies impinges upon inmates'
Eighth Amendment rights as discussed above, the prisoner would have to address
the following issues: (1) whether a valid, rational connection exists between the
prison regulation and the legitimate governmental interest that purportedly
justifies it; (2) whether alternative means of exercising the constitutional right
remain open to the prisoners; (3) the impact that accommodating the
constitutional right will have on guards, other inmates, and prison resources; and
(4) whether there are ready alternatives to the prison regulation. 243
Prisoners denied access to potentially life-saving experimental treatments
because of a prison regulation should be able to establish all four elements.
Under the Safley test, it is not enough for state officials merely to articulate a
reason for their decision. Rather, the officials' reasoning is subjected to judicial
scrutiny. 244 The Safley test has served as a basis for invalidating prison policies
in several cases. The case of Muhammad v. Pitcher/45 for example, involved a
prison policy of treating inmate mail from the State Attorney General's Office
as ordinary mail rather than legal mail and opening it while the addressee was not
present. 246 The court found that opening the mail in the absence of the prisoners
burdened the inmates' First Amendment rights and was not reasonably related to
legitimate penological interests. 247 Contrary to the defendant's contentions, the
court found that a requirement that mail from the Attorney General's Office be
opened only in the presence of the addressee would not waste prison resources. 248
Moreover, treatment of mail from the Attorney General as ordinary mail left no
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See Moore, supra note 219, at 571-72.
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alternative for prisoners who wished to communicate confidentially with the
Attorney General in order to redress grievances. 249 Similarly, in Castillo v.
Gardner, 250 the court found that a prison policy of conducting digital rectal
probes without cause failed the Turner v. Safley test because it was not
reasonably related to a legitimate penological goal. 251
In the case of a policy barring access to clinical research, the governmental
entity promulgating the regulation would presumably assert that the reason for
its regulation is the protection of prisoners against the abuses of biomedical
experimentation. As discussed above, however, DHHS regulations implement
multiple safeguards to protect prison populations. 252 In light of these regulatory
requirements and precautions, it will be difficult for prison authorities to justify
complete denial of access to clinical trials as a reasonable antidote to prisoner
abuse. 253
If promising treatment for a particular disease is available to the inmate only
through an experimental study, as is often the case for AIDS patients/54 prisoners
will have no alternative and no way to exercise their constitutional right to
medical treatment outside of the clinical trial. In some cases, last-chance
experimental therapies provided through clinical trials constitute the only
meaningful healthcare available to a terminally ill patient. Prisoners seeking
participation in such biomedical research will therefore be able to prevail with
respect to the second element of the Safley test.
The third element of the Safley test might provide the greatest hurdle for
inmates challenging a prison regulation that prohibits access to clinical trials, but
it should not be insurmountable.
Prison officials might argue that
accommodation of the prisoner's desire to participate in a study may have an
adverse impact on guards, other inmates, and prison resources. The prison may
contend that special treatment of some prisoners for medical research purposes
might cause jealousy among inmates, require additional security measures for
prisoners transported to and from the medical site, and result in added costs for
the correctional facility.
The inconvenience for correctional institutions allowing prisoner
participation in clinical trials, however, should be minimal. Under FDA
regulations, sponsors of drug studies are generally required to pay for the
investigational drugs provided in trials. 255 Consequently, the drug companies

249. See id.
250. 854 F. Supp. 725 (E.D. Wa. 1994).
251. See id. at 726.
252. See discussion supra Part III.
253. The state might also argue that the regulation is necessary for security and cost reasons.
Allowing an inmate to leave the prison in order to receive the experimental treatment could
potentially raise expenses and security concerns for prison authorities. These arguments are
addressed with respect to the third element of the Safley test below.
254. See Kelly, supra note 131.
255. See 21 C.F.R. § 312. 7(d)(l)(1999). "Charging for an investigational drug in a clinical
trial under an IND is not permitted without the prior written approval of FDA. In requesting such
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themselves pay for the treatment of prisoners who receive experimental therapy
in clinical research. 256 Moreover, during the 1960s, prior to the constraints
imposed by federal regulations, drug companies competed for access to prisoner
populations. 257 Upjohn and Parke-Davis built a state of the art laboratory inside
the State Prison of Southern Michigan at Jackson. 258 If researchers were
encouraged to utilize prisoners in clinical trials that would benefit both the
sponsors and the prisoners, as required by the regulations, drug companies and
research institutions may once again be eager to provide medical facilities within
the prisons at which the studies would be conducted. In the past decade,
researchers in Maryland and Colorado have in fact conducted AIDS-related
clinical trials at correctional facilities. 259 At other locations, clinical studies have
taken place at hospitals that provide routine medical services to prisoners and to
which prisoners are transported for healthcare on a regular basis. 260
In addition, experience has shown that prisoners do not vie with one another
for the opportunity to be research subjects and that there is often a dearth of
inmates willing to participate in clinical research. 261 Therefore, it is unlikely that
the availability of experimental protocols for seriously ill inmates will be
perceived as favoritism and cause morale problems within the prison. On the
contrary, all prisoners might be reassured by the enhanced quality of the medical
care and the new treatment opportunities available at the correctional facility.
The cost and inconvenience for prison authorities would thus be slight.
With respect to the fourth element of the Safley test, it should not be difficult
to show that prison authorities wishing to protect prisoners from coerced or
uninformed participation in clinical research or from abusive medical practices
have ready alternatives to an absolute ban on access to clinical studies. Prison
authorities could ensure that an appropriately constituted IRB has approved the
proposed clinical study and that all other regulatory requirements are being
followed by those conducting the research. In this manner, prison officials will
be able to protect the prison population without denying seriously ill patients
potentially life-saving therapy.

approval, the sponsor shall provide a full written explanation of why charging is necessary in order
for the sponsor to undertake or continue the clinical trial, e.g., why distribution of the drug to test
subjects should not be considered part of the normal cost of doing business." !d.
256. See id. Ifthe inmate receives standard therapy in a control arm, the drug sponsor does
not have to cover the expense. However, this does not add costs for the state since the patient
would have to be treated with standard therapy at the state's expense if no experimental therapy
were available.
257. See HORNBLUM, supra note 5, at 103.
258. See id.
259. See Kelly, supra note 131, at 61.
260. See id. at 60.
261. See Bailey v. Lally, 481 F. Supp. 203, 220 (D. Md. 1979); STEIN & HEADLEY, supra
note 152, at 21 ("The [prison] population is not very anxious to participate.").
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B. The Fourteenth Amendment Does Not Bar Prisoner Access to
Experimental Treatment and May, in Fact, Mandate
Inmates' Inclusion in Clinical Trials
1. Due Process and Equal Protection.-The Fourteenth Amendment
provides that no state may "deprive any person of life, liberty, or property,
without due process of law; nor deny to any person within its jurisdiction the
equal protection of the laws." 262 The Supreme Court has stated that "[d]ue
process of law is a summarized constitutional guarantee of respect for those
personal immunities which ... are 'so rooted in the traditions and conscience of
our people as to be ranked as fundamental' 263 •.• or are 'implicit in the concept
of ordered liberty."'264 Traditionally, the Supreme Court has held that a state
violates substantive due process when its acts "shock the conscience" of
humanity. 265
Governmental action is subjected to strict scrutiny if it impermissibly
interferes with the exercise of a fundamental right or disadvantages a suspect
class. 266 If no fundamental right or particular suspect class is adversely affected,
the challenged governmental action will be assessed under "rational basis
scrutiny" to determine whether it bears a rational relationship to a legitimate
governmental interest. 267 The Supreme Court has determined that the
fundamental rights protected by the Due Process Clause include the rights to
marry, to marital privacy and contraception, to abortion, to have children, to
control the education and upbringing of·one's children, to bodily integrity, and
to refuse unwanted lifesaving medical treatment. 268 The suspect classifications
that warrant strict scrutiny under the Equal Protection Clause are race, alienage,
and national origin. 269
The Bailey70 court held that the defendants' conduct did not rise to the level
of a constitutional due process violation. 271 The court acknowledged that some
of the living conditions that were prevalent at MHC at the time were
unacceptable and, that the research studies offered prisoners a partial escape from

262. U.S. CONST. amend. XIV.
263. Rochin v. California, 342 U.S. 165, 169 (1951) (citing Snyder v. Massachusetts, 291
U.S. 97, I 05 (1934)).
264. !d. (citing Palko v. Connecticut, 302 U.S. 319, 325 (1937)).
265. See Bailey, 481 F. Supp. at 219 (citing Rochin, 342 U.S. at 172).
266. See Massachusetts Bd. of Retirement v. Murgia, 427 U.S. 307, 312 (1976).
267. See Harris v. McRae, 448 U.S. 297, 326 (1980).
268. See Washington v. Glucksberg, 521 U.S. 702, 719-20 (1997).
269. See Cleburne v. Cleburne Living Ctr., Inc., 473 U.S. 432, 440 (1985). An intermediate
level of scrutiny has been applied in cases involving classification based on sex or illegitimacy. See
Clark v. Jeter, 486 U.S. 456, 461 (1988). To be upheld, a classification analyzed under the
intermediate level of scrutiny must be substantially related to an important governmental objective.
See id.
270. 481 F. Supp. at 203.
271. See id. at 225.
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those conditions and an opportunity for higher eamings.272 These circumstances
suggest that the prisoners might have enrolled in the clinical trials not because
they wished to participate in the biomedical research and understood its purpose
and implications, but solely because they hoped to escape some of the intolerable
prison conditions. Prisoners who underwent experimentation for which they did
not provide meaningful consent arguably suffered a violation of their right to
bodily integrity or liberty. Nevertheless, considering all the evidence in the case
and the informed consent provided by participants, the court found that the
inclusion of inmates in the medical experiments at issue did not "shock the
conscience" or defy constitutional standards.Z73
On the other hand, prisoners who desire access to experimental treatment and
are denied permission to participate in a clinical trial may be able to establish that
their exclusion from therapeutic medical research violates the Fourteenth
Amendment. Although federal law permits the inclusion of prisoners in c1 inical
trials in limited circumstances, state laws and correctional policies continue to
prohibit prisoners' access to biomedical studies in many jurisdictions.274
Prisoners may challenge state laws or regulations barring access to clinical trials
by asserting that the state action violates the due process and equal protection
clauses of the Fourteenth Amendment. They may contend that the state is
depriving them of the liberty to enjoy the benefits of clinical research or is
endangering their lives if it is precluding access to potentially life-saving
treatment. Likewise, they may argue that they are subjected to unequal treatment
based on their status as prisoners.
InFante v. Department ofHealth and Human Services, 275 prisoners from the
State Prison of Southern Michigan at Jackson challenged proposed FDA
regulations limiting prisoner access to clinical trials on due process and equal
protection grounds?76 Cecil Cone, an inmate who had volunteered to participate
in trials involving radioactive tracers, tuberculosis tests, medicated skin lotions,
and antacids, stated that he wished to continue participating in nontherapeutic
studies because they relieved the sheer boredom of prison life and allowed him
to supplement his meager prison income.277 The drug testing, according to Cone,
provided "a change of pace. It's like a little vacation." 278 In addition, the money
provided a powerful incentive. 279 The FDA apparently found the prisoners'
arguments to be compelling because it withdrew its proposed regulations and

272. Seeid.at219.
273. See id.
274. See Kelly, supra note 131, at 58.
275. Civil Action No. 80-727788 (E.D. Mich. filed July 29, 1980), cited in 46 Fed. Reg.
35085 (1981).
276. See Schroeder, supra note 3, at 986.
277. See Marjorie Sun, Inmates Sue to Keep Research in Prisons, 212 SCIENCE 650, 650
(May 8, 1981).
278. /d.
279. See id.
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never reissued a different proposal. 280 However, no court decision was issued
regarding the question of the prisoners' constitutional rights.
The prisoners in the Fante case argued that the proposed FDA regulations
would deprive them of the liberty to enjoy the benefits of clinical research
without due process of law and that they were denied the equal protection of the
law because of their status as prisoners. 281 Seriously ill prisoners seeking
participation in clinical trials for medical reasons rather than for income or a
break from routine would have a far more persuasive argument than did the
Fante plaintiffs and may well be able to prevail in a court action.
It must be noted, however, that it will be difficult to establish the existence
of a fundamental right of access to clinical trials for incarcerated individuals.
Although prisoners have a constitutional right to receive medical care in
prison, 282 no court has deemed this fundamental right to extend to
nonconventional, experimental treatments. In addition, prisoners are not among
the identified suspect classes and thus are not entitled to heightened scrutiny
under the Equal Protection Clause. 283 State laws or correctional policies
prohibiting the participation of prisoners in biomedical studies would therefore
be analyzed under the rational basis test.
In defending a Fourteenth Amendment claim, the state would presumably
argue that its reason for precluding prisoners from involvement in biomedical
research is to protect them from coerced or uninformed participation or from the
abuses of irresponsible research. As discussed above, however, existing federal
regulations provide numerous safeguards against research abuses so long as they
are conscientiously implemented by IRBs. 284 The regulations mandate that
prisoners can participate only in studies that will directly benefit the subject or
the inmate population in general and prohibit prisoner involvement in
nontherapeutic clinical trials. 285 Moreover, the regulations implement safeguards
relating to IRB review, selection of subjects, informed consent, and the
performance of the experimentation. 286 In light of these extensive federal
regulations, it will be difficult for the state to establish that a complete ban on
prisoner studies, including those with life-saving potential, bears a rational
relationship to the goal of providing prisoners with meaningful protection. 287 A
state law or policy barring prisoner access to potentially life-saving experimental
therapy may consequently be revoked even under Due Process or Equal
Protection "rational basis" scrutiny.

280. See Kelly, supra note 131, at 56.
281. See Sun, supra note 277, at 650.
282. See Estelle v. Gamble, 429 U.S. 97, 103 (1976).
283. See Cleburne v. Cleburne Living Ctr., Inc., 473 U.S. 432, 440 (1985).
284. See discussion supra Part III.
285. See 45 C.F.R. § 46.306 (1998).
286. See id. §§ 46.304, 46.305.
287. If the state argues that its ban is motivated by concerns about cost and security, these
arguments too will prove weak and could be defeated under the rational basis test. See discussion
supra Part IV.
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It is tempting to assert an Equal Protection argument based on the reality that
minorities are disproportionately affected by bans on studies involving prisoners.
This argument, however, is destined to fail.
Scholars have noted that African Americans and Hispanics constitute a
disproportionately large percentage of the prison population, compared to their
general population rates. 288 African Americans make up approximately half of
the United States' 1.8 prison population, and Hispanics account for fifteen
percent, while only twelve percent of the U.S. population is Black, and eleven
percent is Hispanic. 289 AIDS and other diseases also affect African Americans
and Hispanics disproportionately. 290 As of June 1994, fifty percent of all AIDS
patients were Black or Hispanic. 291 By 1998 Blacks accounted for forty-nine
percent of AIDS deaths, and eighteen percent of AIDS deaths were among
Hispanics. 292 Black men have a higher risk of cancer and cirrhosis of the liver
than non-African American men, and Hispanics report higher rates of heart
disease, cancer, and chronic liver disease than do non-Hispanics. 293
No constitutional claim can be based on these statistics. The Constitution
prohibits only purposeful discrimination, and facially neutral governmental
actions cannot be constitutionally challenged using a disparate impact theory. 294
Nevertheless, the fact that minorities are disproportionately affected by both
imprisonment and particular diseases, provides a compelling reason for the
inclusion of inmates in clinical studies, as will be discussed in Part V.A below.
2. The Right to Privacy.-The constitutional right to privacy is somewhat
amorphous and may be rooted in a variety of provisions. 295 The right to privacy
has been described most often as stemming from the Fourteenth Amendment's
concept ofpersonalliberty. 296 It may also be found in the Ninth Amendment's
reservation of rights to the people. 297 In Griswoldv. Connecticut, 298 the Supreme
Court determined that "the First Amendment has a penumbra where privacy is
protected from governmental intrusion."299 The right to privacy also includes the
right to be free from governmental surveillance and intrusion in one's private
affairs, which stems from the Fourth Amendment. 300

288. See Kelly, supra note 131, at 51.
289. See Michael A. Fletcher, The Crime Conundrum; Policing Is Tougher, Jails Fuller, and
Crime Is at a 30-Year Low, WASH. POST, Jan. 16, 2000, at Fl; Shapiro, supra note 16, at 2A.
290. See Fletcher, supra note 289, at Fl; Shapiro, supra note 16, at 2A.
291. See Fletcher, supra note 289, at Fl; Shapiro, supra note 16, at 2A.
292. See Karen Gullo, Clinton to Seek AIDS Funds, AP ONLINE, Jan. 18, 2000 (citing CDC
figures).
293. See Marquart et al., supra note 208, at 188.
294. See Washington v. Davis, 426 U.S. 229 (1976).
295. See Whalen v. Roe, 429 U.S. 589, 598-99 nn.23-25 (1977).
296. See id. n.23 (citing Roe v. Wade, 410 U.S. 110, 153 (1973)).
297. See id.
298. 381 U.S. 479 (1965).
299. !d. at 483.
300. See Whalen, 429 U.S. at 599 n.25.
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289. See Michael A. Fletcher, The Crime Conundrum; Policing Is Tougher, Jails Fuller, and
Crime Is at a 30-Year Low, WASH. POST, Jan. 16, 2000, at Fl; Shapiro, supra note 16, at 2A.
290. See Fletcher, supra note 289, at Fl; Shapiro, supra note I6, at 2A.
291. See Fletcher, supra note 289, at Fl; Shapiro, supra note I6, at 2A.
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The right to privacy generally encompasses the right to maintain
confidentiality regarding medical information, and some courts have held that
even prisoners enjoy this right, particularly with respect to HIV status. 301 Other
courts have found, however, that inmates do not retain a constitutional right to
the confidentiality of their medical records. 302 Prisoners do, nonetheless, have
a restricted constitutional right to bodily privacy. 303
The Bailey 04 court only briefly addressed the privacy issue. It found the
plaintiffs' privacy claims to be unfounded because the prisoners volunteered for
the experimental procedures at issue and were not subjected to involuntary
treatment as was the case in the precedents they cited. 305 Likewise, under
contemporary regulatory guidelines, prisoner enrollment cannot be coerced.
Thus, it is highly unlikely that biomedical research will give rise to violation of
constitutional privacy rights.
A related but different claim may arise from the Fourth Amendment, which
establishes "[t]he right of the people to be secure ... against unreasonable
searches and seizures."306 Invasive medical procedures, such as blood tests, can
constitute searches and seizures that impinge upon the constitutional rights of the
patient, even in the prison context. 307 The Bailey court did not address any
potential search and seizure claims. Nevertheless, if bodily fluids are extracted
from prisoners who have not provided informed consent, Fourth Amendment
violations may arise. Clinical studies that comply with DHHS regulations
requiring voluntariness and informed consent, however, should not infringe upon
any participant's right to be free of unreasonable searches and seizures.
If prisoners provide genuine informed consent to biomedical
experimentation, if the study is thoroughly reviewed by an IRB, and if the
research conforms to the guidelines of federal regulations, then sufficient
safeguards will be implemented to assure that the subjects' rights to bodily
integrity and privacy will not be sacrificed. Nevertheless, a significant concern
exists that adequate confidentiality regarding medical records may not be
maintained in the prison setting. The DHHS regulations governing research
involving inmates do not address the issue of confidentiality. 308 As discussed
below, precautions must be taken to assure confidentiality for inmate
participants.

301. See, e.g., Harris v. Thigpen, 941 F.2d 1495, 1513 (11th Cir. 1991); Clarkson v.
Coughlin, 898 F. Supp. 1019, 1041 (S.D.N.Y. 1995); Nolley v. County ofErie, 776 F. Supp. 715,
729-31 (W.D.N.Y. 1991).
302. See Tokarv. Armontrout, 97 F.3d 1078, 1084 (8th Cir. 1996); Anderson v. Romero, 72
F .3d 518, 524 (7th Cir. 1995).
303. See Covino v. Patrissi, 967 F.2d 73, 78 (2d Cir. 1992).
304. Bailey v. Lally, 481 F. Supp. 203 (D. Md. 1979).
305. See id. at 221.
306. U.S. CONST. amend. IV.
307. See Stanley v. Swinson, No. 93-16078, 1995 WL 46181, at *4 (9th Cir. Feb. 6, 1995);
Thompson v. City of Los Angeles, 885 F.2d 1439, 1447 (9th Cir. 1989).
308. See discussion supra Part III.
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Constitutional concerns do not justify the exclusion of prisoners from
medical research. It is arguable that the Eighth and Fourteenth Amendments
mandate the provision oflife saving therapy to seriously ill prisoners even if the
treatment is available only through a clinical trial. While inmate participation in
clinical trials may be hampered by certain practical hurdles, these obstacles are
not insurmountable, as demonstrated by several programs that successfully
integrate prisoners into research protocols. 309 The following section will discuss
the experience of medical institutions that include prisoners in therapeutic
clinical studies and will outline recommendations to facilitate the implementation
of such programs.
V. POLICY ISSUES AND RECOMMENDATIONS

A. Several Jurisdictions Recognize the Importance of Including
Prisoners in Clinical Trials
In July 1995 the New Jersey Community Research Initiative issued a report
entitled Prisoners with HIV· Guidelines for Implementing Clinical Trials in
Correctional Settings .310 The report found that"[ m]any leaders in medical ethics
have concluded that the coercive nature of correctional settings should not
prevent prisoners from participating in medically appropriate clinical studies. " 311
It cited the findings of a 1989 consensus panel of leaders in corrections, prison
health care, and public health that likewise found that "although a prison setting
precludes the voluntary and uncoerced choice classically envisioned by the
federal regulations, prisoners should be permitted to choose to participate in
therapeutic trials . . . that hold out the possibility of benefit. " 312 The report
further noted that "public health officials, including the World Health
Organization and the former National Commission on AIDS, have advocated
prisoner access to clinical research." 313
Including prisoners in biomedical studies is important for reasons that go
beyond benefits to the subjects themselves. Traditionally, African Americans,
Hispanics, intravenous drug users, and women have been underrepresented in
clinical trials. 314 Two important studies in which AZT was tested were
conducted with a population that was more than ninety-two percent White and
male. 315 A 1991 report produced by the AIDS Clinical Trial Group concluded
that African Americans made up only ten percent of participants in this national
consortium of clinical trials, Hispanics twelve percent, and IV drug users and
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women accounted for eleven percent and six percent, respectively. 316
Researchers have found that members of different races at times respond to
treatments in different ways. 317 Whites and Blacks, for example, respond
differently to hypertensive therapy. 318 Women may respond differently from men
because of variations in size, body fat, and hormonal levels. 319 Similarly, the
efficacy of drugs may be significantly affected by other drugs, including illegal
substances taken by the patient. 320 Exclusion of minority subjects from drug
studies is thus "bad science" and will adversely impact both the researcher and
future patients. 321 The prison environment provides a diverse population, with
a high concentration of minorities. Allowing prisoners to participate in
therapeutic clinical studies will benefit not only the inmate patients, but also the
medical community and society at large.
Research institutions in several states have succeeded in integrating prisoners
into clinical trials. In Texas, Virginia, and New York research entities provided
standard medical care to prisoners before establishing programs that included
inmates in clinical studies. 322 In Texas, the University of Texas Medical Branch
at Galveston ("UTMB") has served as the primary prison hospital for the Texas
Department of Criminal Justice ("TDCJ") since 1983. 323 It is staffed by security
personnel who report to TDCJ and health care professionals who answer to the
University. 324 For many years, Texas inmates have been enrolled in clinical trials
involving protocols that may be of direct benefit to them. 325 Historically, the
majority of the studies at UTMB in which prisoners have been included have
been cancer-related, but an increasing number in recent years have focused on
AIDS treatment. 326
In New York City, the Spellman Center for HIV-Related Disease at St.
Clare's Hospital has provided care to many HIV-infected New York inmates and
involved prisoners in clinical trials for several years beginning in 1986. 327 In
Albany, New York, Albany Medical College provides hospital care for prisoners
in twenty-five correctional facilities. 328 The facility began enrolling prisoners in
AIDS-related trials in 1988 and included inmates in oncologic clinical trials in
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prior years. 329 The Division of Infectious Diseases at the Medical College of
Virginia has served the Virginia state prison population since 1985 and has
enrolled prisoners in clinical trials since 1990. 330
Not all research institutions that include inmates in medical studies provide
healthcare services to prisoners outside of clinical trials. 331 Johns Hopkins
University in Maryland has established several AIDS-related clinical trials in
Maryland prisons since 1991, although it is not otherwise a provider of treatment
for Maryland prisoners. 332 In Colorado, the Department of Health has also
allowed prisoner participation in AIDS-related trials. 333 Likewise, Yale
University Medical School has worked with prisoners in medical research
studies. 334
B. The Challenges of Prisoner Involvement in Clinical Trials
The commentators who advocate the inclusion of prisoners in clinical studies
recognize the existence of certain obstacles inherent to the prison setting. 335
Nevertheless, the obstacles are not insurmountable, as evidenced by the fact that
research is successfully conducted by some institutions, as discussed above.
1. Confidentiality.-Prisoners participating in AIDS-related clinical trials
risk disclosure of their HIV status either because it is obvious that they are
receiving frequent and specialized medical care or because ofthe prison's recordkeeping policies. 336 Disclosure ofillV status may be particularly dangerous for
inmates because of the risk that other prisoners or correctional officers will
subject the patient to persecution and violence. 337
The Forum on Prisoner Access to Clinical Trials in New Jersey
acknowledged that maintaining fully effective confidentiality in the prison setting
is nearly impossible. 338 However, it suggested several alternatives to safeguard
the privacy of research participants. Although it is not clear that prisoners retain
a right to confidentiality regarding HIV status, 339 every effort should be made to
prevent disclosure ofinmates' receipt ofHIV -related experimental therapy. Such
precautions will safeguard the prisoners' constitutional rights to the extent they
exist, will encourage inmates to participate in clinical trials, and will reduce
prisoner grievances and litigation regarding confidentiality matters. Where the
research institution provides routine medical care to inmates and frequently sends
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staff to the correctional facility, it is easiest to maintain confidentiality for
clinical trial enrollees. Inmates should be allowed to communicate directly with
investigators about clinical trials without having to request permission from
prison officials. 340 Investigators could publicize the research through newsletters
or postings that are seen by all inmates. Enrollment could then occur during a
routine medical visit by the institution's staff rather than on a day specifically
designated for discussion of the AIDS-related study. 341
Moreover, the Forum on Prisoner Access to Clinical Trials recommends that
medical records that contain information about HIV status be maintained in
secured areas that can be accessed only by medical personnel directly responsible
for the inmate's treatment. 342 Correctional officers and other inmates should not
have access to sensitive medical records even if they are assigned to work in the
prison's medical department. 343
Finally, the Forum suggests that prisoners also have confidential access to
investigators in the event that they suffer adverse side effects from
investigational drugs. 344 Prisoners involved in clinical trials should be allowed
to place collect calls to designated medical personnel or to an answering service
twenty-four hours a day. 345 In Maryland, investigators are available by beeper
around the clock. 346 Where telephone usage by prisoners is restricted, however,
inmates may be limited to reaching research staff through prison medical
personnel and thus may be forced to disclose confidential information to
correctional officials. 347
2. Logistics and Communication.-Transportation issues may constitute
another hurdle to prisoner participation in biomedical research. 348 Where studies
are conducted in correctional facilities, researchers must travel to prison clinics,
bringing with them all necessary medical equipment and carrying out of the
prison bodily fluid samples for testing. 349 They must also undergo timeconsuming security checks each time they arrive at the prison. 350 Where clinical
trials are conducted on hospital grounds, prisoners must be transported under
guard to and from the hospital. Significant delays are often caused by prison
lockdowns, inmate counts, and other security precautions. 351
Restrictions on items that can be possessed by prisoners may also be
problematic for clinical research purposes. Since bottles and pills are contraband
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in most prisons, procedures must be implemented to allow prisoners to keep
experimental drugs with them or to have them administered in a manner that
maintains confidentiality. 352 In some New Jersey jails prisoners have a selfdosing system for their prescription medications that features locked boxes. 353
A similar mechanism could be implemented in other prisons, though correctional
officers would have to be educated to maintain confidentiality regarding the
nature of prisoners' medications and any modifications of general prison policies
that apply to clinical trial participants. 354
Another problem may arise in instances where prisoners are transferred from
one facility to another. 355 Inmates should be able to continue receiving the
experimental treatment at the new facility. 356 A "medical hold" could be placed
on trial participants designated for relocation so that the central administration,
in consultation with medical investigators, may evaluate whether the transfer will
cause any adverse consequences to the patient or the research study. 357 Thus,
prison administrators will avoid potential violation of the inmates' Eighth
Amendment right to adequate medical care and will not jeopardize the prisoners'
health by sudden and unmonitored discontinuation of experimental treatment.
Similarly, continuity of care should be assured for prisoners who are paroled
or released. 358 In Maryland, a research nurse meets with the prisoner prior to
release and encourages the individual to continue trial participation once
released. 359 Researchers should offer former prisoners assistance with
transportation to and from the research site and work with parole officers to
assure appropriate sustained treatment. 360
A recent statement issued by the Office of the Inspector General of the U.S.
Department of Health and Human Services is highly critical of the institutional
review board system. 361 It noted that a "1995 Advisory Commission on Human
Radiation Experiments found in their interviews with actual research subjects
that few realized they were participants in research and many had little
understanding of the informed consent forms they signed. " 362 The statement
further denounced the limited continuing review conducted by most IRBs that,
burdened by ever-increasing workloads, do no more than review paperwork
submitted by research investigators and fail to solicit feedback from research
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subjects. 363 The Office of the Inspector General also urged research institutions
to provide adequate education for IRB members concerning ethical issues and
scientific questions and noted that currently IRB training is minimal to
nonexistent. 364
As discussed throughoutthis Article, IRBs approving clinical trials involving
prisoners must meet stringent requirements that are inapplicable to reviews of
other studies. The IRB must include a prisoner advocate, review the proposed
study in light of guidelines specific to the prison setting, and provide prisoners
with data presented in language that they can understand. 365 IRBs are therefore
likely to review protocols involving prisoners more meticulously than they might
review other research proposals. Nevertheless, the comments of the Office of
Inspector General are prudent admonitions for anyone reviewing research
protocols designed to include prisoner participants. IRBs should be well versed
in the ethical dilemmas that are potentially involved in prisoner research, must
ensure that meaningful informed consent is obtained, and should conduct
thorough and conscientious continuing reviews of the clinical trials in question.
CONCLUSION

Although federal regulations permit the inclusion of prisoners in therapeutic
clinical trials from which they may gain direct treatment benefits, prisoners are
able to enroll in clinical trials in only a few locations. 366 Although perhaps wellintentioned, policies that ban the inclusion of inmates in biomedical studies are
detrimental to prisoners, to science, and to society at large because they preclude
research utilizing a particularly diverse and disadvantaged segment of society.
In the words of Justice Brandeis:
Experience should teach us to be most on our guard to protect liberty
when the Government's purposes are beneficent. Men born to freedom
are naturally alert to repel invasion of their liberty by evil-minded rulers.
The greatest dangers to liberty lurk in insidious encroachment by men of
zeal, well-meaning but without understanding. 367
Clinical trials that comply with federal regulations will not violate any of the
participants' constitutional rights. In Bailey v. Lally,368 the court found no
constitutional violations despite extremely harsh prison conditions that often
motivated prisoner participation in research studies that were nontherapeutic and
had not been scrutinized by a reviewing entity such as an IRB? 69 In light of
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contemporary regulations, it is difficult to imagine that any subsequent court
would deem voluntary participation in therapeutic studies to impinge upon the
constitutional rights of an enrollee.
The exclusion of seriously ill prisoners from clinical trials through which
they may receive potentially life-saving treatment is constitutionally dubious and
morally troubling. It is arguable that prisoners have a right to participation under
the Eighth Amendment, the Due Process clause, and the promise of Equal
Protection. In addition, moral considerations impel the allowance of prisoner
enrollment in therapeutic biomedical research. Two commentators have
summarized the arguments well:
Inmates as a group ... need to be provided with access to clinical trials
of new and innovative therapies that present the possibility of direct
benefit. . . . They must be presented with the opportunity for informed
choice when appropriate, despite recognition that the systematic
deprivations and inherent coerciveness of the institutions and the
desperate character of HIV infection compromise the consent process.
As in other areas of public policy and public health, HIV infection
demands a fresh examination of equity and justice. Whether access is
provided to promising investigational therapies will measure the mettle,
courage, inventiveness, and flexibility of the medical research
community. It will also test the humanity of correctional administrators,
who must provide the setting and support services to permit the conduct
and monitoring of clinical trials. 370
Policy makers, legislators, and prison authorities must meet the challenge of
providing appropriate treatment for seriously ill prisoners, including that which
is available through experimental protocols. To fail to do so would defy the
"broad and idealistic concepts of dignity, civilized standards, humanity, and
decency" 371 embodied in the Constitution and in American jurisprudence.

370. STEIN & HEADLEY, supra note 152, at 38 (quoting Nancy NeveloffDubler & Victor W.
Side!, On Research on HJV Infection, JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
174,204 (1994)).
371. Jackson v. Bishop, 404 F.2d 571, 579 (8th Cir. 1968).
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